Show simple item record

dc.contributor.authorWeisel, Katja
dc.contributor.authorDimopoulos, Meletios
dc.contributor.authorMoreau, Philippe
dc.contributor.authorYagci, Munci
dc.contributor.authorLarocca, Alessandra
dc.contributor.authorKanate, Abraham S
dc.contributor.authorVural, Filiz
dc.contributor.authorCascavilla, Nicola
dc.contributor.authorBasu, Supratik
dc.contributor.authorJohnson, Peter
dc.contributor.authorByeff, Peter
dc.contributor.authorHus, Marek
dc.contributor.authorRodriguez-Otero, Paula
dc.contributor.authorMuelduer, Ercan
dc.contributor.authorAntilla, Pekka
dc.contributor.authorHayden, Patrick J
dc.contributor.authorKrauth, Maria-Theresa
dc.contributor.authorLucio, Paulo
dc.contributor.authorBen-Yehuda, Dina
dc.contributor.authorMendeleeva, Larisa
dc.contributor.authorGuo, Shien
dc.contributor.authorYu, Xin
dc.contributor.authorGrote, Lara
dc.contributor.authorBiyukov, Tsvetan
dc.contributor.authorDhanasiri, Sujith
dc.contributor.authorRichardson, Paul
dc.date.accessioned2020-08-27T15:53:51Z
dc.date.available2020-08-27T15:53:51Z
dc.date.issued2020-01-01
dc.identifier.citationWeisel, K., Dimopoulos, M., Moreau, P. and Yagci, M. (2020) Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma, Leukemia & Lymphoma, 61 (8), pp. 1850-1859, DOI: 10.1080/10428194.2020.1747066en
dc.identifier.issn1042-8194en
dc.identifier.pmid32268815 (pubmed)
dc.identifier.doi10.1080/10428194.2020.1747066en
dc.identifier.urihttp://hdl.handle.net/2436/623533
dc.descriptionThis is an accepted manuscript of an article published by Taylor & Francis in Leukemia & Lymphoma on 09/04/2020, available online: https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1747066 The accepted version of the publication may differ from the final published version.en
dc.description.abstractIn the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM), including lenalidomide refractory patients. Here, we report health-related quality of life (HRQoL) results from this trial. Patients received PVd or Vd in 21-day cycles until disease progression or discontinuation. HRQoL was assessed using the EORTC QLQ-C30, QLQ-MY20, and EQ-5D-3L instruments on day 1 of each treatment cycle. Mean score changes for global QoL, physical functioning, fatigue, side effects of treatment domains, and EQ-5D-3L index were generally stable over time across treatment arms. The proportion of patients who experienced clinically meaningful worsening in global QoL and other domains of interest was similar. These HRQoL results with PVd along with previously demonstrated improvement in PFS vs Vd continue to support its use in patients with RRMM.en
dc.description.sponsorshipThis work was supported by Celgene Corporation.en
dc.formatapplication/pdfen
dc.languageeng
dc.language.isoenen
dc.publisherInforma UK Limiteden
dc.relation.urlhttps://www.tandfonline.com/doi/full/10.1080/10428194.2020.1747066en
dc.subjectHRQoLen
dc.subjectquality of lifeen
dc.subjectbortezomiben
dc.subjectdexamethasoneen
dc.subjectmultiple myelomaen
dc.subjectpomalidomideen
dc.titleHealth-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myelomaen
dc.typeJournal articleen
dc.identifier.eissn1029-2403
dc.identifier.journalLeukemia and Lymphomaen
dc.date.updated2020-08-24T09:21:44Z
dc.contributor.institutionUniversity Medical Center of Hamburg-Eppendorf, Hamburg, Germany and University Hospital of Tuebingen, Tuebingen, Germany.
pubs.place-of-publicationUnited States
dc.date.accepted2020-03-15
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW27082020SBen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2021-04-09en
dc.source.volume61
dc.source.issue8
dc.source.beginpage1850
dc.source.endpage1859
dc.description.versionPublished version
refterms.dateFCD2020-08-27T15:52:17Z
refterms.versionFCDAM


Files in this item

Thumbnail
Name:
Basu_Health_Related_Quality_20 ...
Size:
1.100Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/